Theriva Biologics (TOVX) revenue and earnings history
Theriva Biologics's annual figures for 16 fiscal years, as filed with the SEC.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$24.1M | — | −$16.7M | $35K | −$16.7M | $654K | — | — | $13.1M | $1.67M | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Theriva Biologics (TOVX) on OQRO.
Common questions
Has Theriva Biologics been profitable?
It reported a net loss in 14 of the years shown (2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023). The highest net income was −$1.71M in fiscal 2010.
What was Theriva Biologics's free cash flow in fiscal 2025?
−$16.7M: operating cash flow of −$16.7M minus capital expenditure of $35K. OQRO calculates free cash flow this way from the two filed lines.
Does Theriva Biologics buy back shares or pay dividends?
None of the 16 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Theriva Biologics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
